Want to join the conversation?
Jason Mills with Canaccord probes on why AngioVac is not gaining traction more quickly and how the company is looking to reinvigorate the growth of AngioVac. $ANGO said that in the past there was some extra product in the marketplace, so there was no bump up in sales. Over time, the company has to define its strategy better than it has before.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.